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SUMMARY 
Aim: To test the hypothesis of an association between polymorphism in FCGR3A (the gene coding for FcγRIΠa, 
which is expressed on macrophages and natural killer cells. is involved in antibody-dependent cell-mediated 
cytotoxicity and has recently been associated with a positive response to rituximab, a recombinant 
immunoglobulin G1 antibody used in non-Hodgkin's lymphomas) and response to infliximab in Crohn's disease. 
Methods: FCGR3A-158 polymorphism was determined using an allele-specific polymerase chain reaction assay 
in 200 Crohn's disease patients who had received infliximab for either refractory luminal (n = 142) or fistulizing 
(n = 58) Crohn's disease. Clinical and biological responses (according to C-reactive protein levels) were assessed 
in 200 and 145 patients, respectively. 
Results: There were 82.9% clinical responders in V/V patients vs. 72.7% in V/F and F/F patients (N.S.). 
Globally, the decrease in C-reactive protein was significantly higher in V/V patients than in F carriers (P = 
0.0078). A biological response was observed in 100% of V/V patients, compared with 69.8% of F carriers (P = 
0.0002: relative risk, 1.43: 95% confidence interval, 1.27-1.61). In the sub-group of patients with elevated C 
reactive protein before treatment. the multivariate analysis selected the use of immunosuppressive drugs and 
FCGR3A genotype as independent factors influencing the clinical response to infliximab (P = 0.003). 
Conclusion: Crohn's disease patients with FCGR 3A-158 V/V genotype have a better biological and, possibly, 
clinical response to infliximab. 
 
INTRODUCTION 
Infliximab is a chimeric monoclonal inmmunoglobulin G1 (IgG1) antibody against tumour necrosis factor-α 
(TNF-α).1 It is effective in refractory and listulizing Crohn's disease.2, 3 In controlled trials. as well as in routine 
practice, the response rate to first treatment is around 75%. with half the responders showing a complete 
response and half a partial clinical response.2-5 Certain demographic and clinical characteristics, including a 
young age,6 colonic location of the disease,6 co-treatment with immunosuppressive drugs6. 7 and non-smoking,7 
have been associated with a positive response to the drug. Furthermore, some patients seem to be biologically 
predisposed to a non-response to infliximab, as manifested by the inefficacy of re-treatment in these patients.2. 8 
Pharmacogenetic hypotheses have been suggested to explain this phenomenon. Studies conducted on TNF-α and 
TNF receptor gene polymorphisms.9-11 as well as on NOD2/ CARD15 gene mutations.12- 13 have disclosed no 
strong association, although an association was suggested with a haplotype in the TNF-β (lymphotoxin-α) gene 
in a relatively small cohort.8 and with the 5q31/IBD5 Crohn's disease risk haplotype in a larger cohort.11 A better 
understanding of the mechanisms of action of infliximab in Crohn's disease may help in the identification of 
candidate genes. In addition to the neutralization of soluble TNF-α and blockade of its effect,14 infliximab most 
probably induces the destruction of some key lamina propria mononuclear and polynuclear cells. 15- 16 The 
binding of infliximab to membrane TNF-α induces apoptosis in monocytes,17 as well as cell lysis by 
complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity.18 Antibody-dependent 
cell-mediated cytotoxicity is an important effector mechanism in the eradication of intracellular pathogens and 
tumour cells. It requires leucocyte receptors for the Fc portion of IgG (FcγR). whose function is to link the IgG-
sensitized antigens to FcγR-bearing cytotoxic cells and to trigger cell activation. Such an antibody-dependent 
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cell-mediated cytotoxicity mechanism has also been suggested in the action of another recombinant IgG1 
antibody, rituximab, used for the treatment of non-Hodgkin's lymphomas. 19- 21 Recently, an important 
pharmacogenetic association has been shown with this antibody. A functionally significant polymorphism in 
FCGR3A.22. 23 the gene coding for FcγRΠIa expressed on macrophages and natural killer cells, was associated 
with clinical and biological responses to rituximab in follicular non-Hodgkin's lymphomas.24. 2S This G → T 
potymorphism is located at nucleotide position +4985 (starting at the ATG initiation codon) in the sixth exon of 
FCGR3A, which is itself located on the long arm of chromosome 1 (lq23), within a cluster of five genes coding 
for the low-affinity FcγR.26 The FcγRIΠa-158V (valine) allotype has a higher affinity for IgG1 than the 
FcγRIIIa-158F (phenylalanine) allotype, and natural killer cells from V/V subjects are more potent in antibody-
dependent cell-mediated cytotoxicity at low antibody concentrations.23 Non-Hodgkin's lymphoma patients with 
the V/V genotype showed a better clinical and biological response to rituximab, suggesting that, in these 
patients, the lysis of lymphomatous cells by antibody-dependent cell-mediated cytotoxicity was more effective, 
through better binding of the Fc portion of rituximab to natural killer cells.24-. 25 Considering the cytolytic 
potential of infliximab, the aim of our work was to search for an association between the FCGR3A-158 




Two hundred patients with Crohn's disease, included between November 1998 and August 2000 in an expanded 
access programme of infliximab in Belgium, were studied. All patients were treated with infliximab for the first 
time. To be included in the expanded access programme, patients had to be between 18 and 65 years of age, 
adopt adequate birth control measures, give informed consent and have one of the following specific inclusion 
criteria: (i) a single or multiple perianal or enterocutaneous draining fistula(e) as a complication of Crohn's 
disease, resistant to conventional treatment for at least 3 months; (ii) moderate to severely active Crohn's disease 
of at least 6 months' duration, with colitis, ileitis or ileo-colitis confirmed by radiography or endoscopy, 
refractory or dependent on oral steroid therapy (> 8 mg/day prednisone equivalent) and/or not responding to 
immunosuppressive agents (azathioprine, 6-mercaptopurine or methotrexate). Approval from the Ethics 
Committee was obtained in April 1998 and patients gave written informed consent for both infliximab treatment 
and pharmacogenetic ancillary studies. The demographic and clinical characteristics of the patients are given in 
Table 1. There were two sub-groups of patients: 142 patients with active luminal (non-fistulizing) disease and 58 
patients with fistulizing disease. Luminal Crohn's disease patients were treated with a single infusion of 
infliximab (5 mg/kg). These patients were followed prospectively for 12 weeks, with physical examination, 
Crohn's disease activity index (CDAI) calculation and C-reactive protein (CRP) measurement (by routine 
procedure) at weeks 0, 4, S and 12. Patients with fistulizing disease were treated with three consecutive infusions 
(5 mg/kg) at weeks 0, 2 and 6. These patients were followed prospectively for 18 weeks, with physical 
examination (including Fistulous track drainage). CDAI calculation and CRP measurement (by routine 
procedure) at weeks 0, 2, 6. 10, 14 and 18. 
Classification of response to infliximab 
The response to infliximab was assessed on the basis of both clinical and biological evolution. Clinically, 
patients were classified as complete responders, partial responders or non-responders according to published 
controlled clinical trials.2. 3 In non-fistulizing disease, patients were considered to be complete or partial 
responders at week 4 according to a decrease in CDAI below 150 or a decrease of 70 points from baseline, 
respectively. Furthermore, according to a recent National Institutes of Health Consensus Conference, we also 
looked at a partial response defined as a decrease of at least 100 points from baseline. In fistulizing disease, 
patients were considered to be complete or partial responders at week 10 according to complete fistula closure or 
a decrease of at least 50% in fistula drainage at two consecutive visits, respectively. Furthermore, the variation in 
CDAI between pre-treatment (week 0) and post-treatment (week 4 or 10) periods was calculated for all patients. 
Biologically, patients were classified as complete, partial or non-responders at 4 weeks (non-fistulizing disease) 
or 10 weeks (fistulizing disease) on the basis of CRP evolution (measured by a routine procedure using 
immunoturbidimetry in local laboratories). This analysis was performed on a sub-group of 145 patients for 
whom CRP values were available before and after treatment and who showed an elevated CRP (greater than 
twice the upper limit of the normal range) before treatment. Patients were classified as complete or partial 
responders according to the normalization of CRP after treatment or a decrease of at least 25% from the baseline 
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level, respectively. Furthermore, for all patients, the variation of CRP (absolute and relative values) was 
calculated between pre-treatment (week 0) and post-treatment (week 4 or 10) periods. 
Table 1. Demographic, clinical and biological characteristics of the study population 
Mean Crohn's disease activity index (± s.d.) 259 (± 116) 
Mean C-reactive protein (normalized) (± s.d.) 11.2 (± 14.6) 
NOD2/CARD15 genotype 
Wild type (%) 137 (68.5) 
Heterozygotes (%| 50 (25.0) 
Homozygotes and compound 13 (6.5) 
heterozygotes (%) 
Female/male (%) 122/78 (61.0/39.0) 
Fistulizing/refractory (%) 58/142 (29.0/71.0) 
Median age (years) (interquartile range) 34 (25-47) 
Disease location 
Ileal (%) 39 (19.5) 
Colonic (%) 69 (34.5) 
Ileo-colonic (%) 81 (40.5) 
Anal involvement (%) 77 (38.5) 
Upper gastrointestinal involvement (%) 11 (5.5) 
Concomitant treatment 
5-Aminosalicylates (%) 94 (47.0) 
Corticosteroids {%) 86 (43.0) 
Azathioprine/6-mereaρtopurine (%) 111 (55.5) 
Methotrexate (%) 15 (7.5) 
Total immunosuppressives (%) 126 (63.0) 
Smoking (%) 68 (34.0) 
 
FCGR3A-158V/F genotyping 
Genomic DNA was isolated using phenol/chloroform extraction, as described previously,12 and stored at -80 °C 
until use. Allele-specific polymerase chain reactions (PCRs) were performed with primers partially based on 
those previously designed by Leppers-van de Straat et al.27 and recently described,28 The forward primer (5'-
TCCAAAAGCCACACTCAAAGTC-3') includes a 3' penultimate mismatch (underlined) lo completely avoid 
FCGR3B amplification and to allow FCGR3A-specilic amplification. The V allele-specific (5'-
GGGGGGCCCCGGGGGTGATGTTCACAGTCTGAGAAGA CACATTTTTACTCCCTAC-3') and the F 
allele-specific (5'-AGACACATTTTTACTCCCATA-3') (Eurobio. Les Ulis, France) reverse primers also 
included new 3' mismatches (underlined) to enhance allele specificity. Moreover, the V allele reverse primer was 
5' elongated (italic characters) to allow single-tube amplification and allele discrimination after electrophoresis. 
PCRs were carried out in a final volume of 25 µL consisting of Taq polymerase buffer (670 mM Tris-HCl pH 
8.8, 160 mM (NH4)2SO4. 0.1% Tween 20), 2 mM MgCl2, 400 µM dNTP (MBI Fermentas, Vilnius, Lithuania), 
20 pmol of the common forward primer, 14.5 pmol of the V allele-specific reverse primer and 30 pmol of the F 
allele-specific reverse primer (all three synthesized by Genset SA, Paris, France), 1 unit of Taq DNA polymerase 
(Eurobio) and 2 µL genomic DNA. PCR was set up in a GeneAmp PCR system 2400 (Perkin Elmer France SA, 
Saint Quentin en Yvelines, France) programmed for an initial denaturation step of 5 min at 95 °C, followed by 
35 cycles at 94 °C for 20 s, hybridization at 58 °C for 20 s and elongation at 72 °C for 20 s. PCR products were 
then analysed by electrophoresis in 8% polyacrylamide gels run in TBE buffer (90 mM Tris-HCl, 90 mM boric 
acid, 2.5 mM ethylenediaminetetra-acetic acid) (Eurobio). After staining with ethidium bromide (Euro-bio), gels 
were visualized using ultraviolet transillumination (Gel Doc 1000 system. Bio-Rad, Hercules. CA, USA) and 
images were captured on a Kodak Digital Science Image (Kodak, Rochester, NY, USA). The F and V allele 
amplification products appeared as bands of 70 bp and 102 bp. respectively. 
Statistical analyses 
CRP values were normalized and expressed as a multiple of the upper limit of the normal range determined in 
each laboratory (95% reference interval, as recommended by the International Federation of Clinical 
Chemistry29). Response rates according to various FCGR3A-158V/F genotypes were compared using the chi-
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squared test. Comparisons were performed between the three genotypes (V/V, V/F, F/F) and also between V 
carriers (V/V, V/F) and non-carriers (F/F), as well as between F carriers (F/F. V/F) and non-carriers (V/V). 
Variations in CDAI between pre- and post-treatment periods (δCDAI) and variations in CRP between pre- and 
post-treatment periods (δCRP) were compared by t-test or Mann-Whitney test as required. 
Multivariate analyses by stepwise logistic regression were performed. An initial analysis was performed, with 
the clinical response as the dependent variable, on a sub-group of 189 patients for whom all the demographic, 
clinical and biological data were available. A second analysis was performed, with the biological response as the 
dependent variable, on a sub-group of 145 patients who showed an elevated CRP before treatment. A third 
multivariate analysis, with the clinical response as the dependent variable, was also performed on this sub-group 
of 145 patients. 
P values of < 0.05 were considered to be significant. 
 
RESULTS 
Clinical and biological responses to infliximab 
Clinically, there were 106 (53.0%). 43 (21.5%) and 51 (25.5%) complete, partial and non-responders, 
respectively, in the study. In patients with non-fistulizing disease, there were 79 (55.6%). 30 (21.1%) and 33 
(23.3%) complete, partial and non-responders. respectively. In patients with fistulizing disease, there were 27 
(46.6%), 13 (22.4%) and 18 (31.0%) complete, partial and non-responders. respectively. Biologically, as 
determined by the decrease in serum CRP, there were 52 (35.9%), 58 (40.0%) and 35 (24.1 %) complete, partial 
and non-responders, respectively. 
Clinical and biological responses to infliximab according to FCGR3A-158V/F genotypes 
There were 35 (17.5%), 100 (50.0%) and 65 (32.5%) PCGR3A-158V/V, V/F and F/F patients, respectively. The 
frequencies of clinical complete, partial and non-responders, according to the PCGR3A genotype, are shown in 
Table 2. There was no significant difference when comparing the various genotypes or V and F carriers and non-
carriers. Even when looking at partial responses delined using more stringent criteria (decrease of at least 100 
points in CDAI), there was still no significant difference between the groups (80.0% responders in V/V patients 
vs. 63.0% responders in V/F and F/F patients: P = 0.11). The median δCDAI was -161 (range, +65 to -427) in 
V/V homozygous patients vs. -116 (range, +135 to -349) in the F carrier group (P = 0.5). The median duration of 
response was 14 weeks (range, 6-104 weeks) in the V/V genotype vs. 12 weeks (range, 1-192 weeks) in the V/F 
and F/F genotypes (P = 0.9).  
The frequencies of biological complete, partial and non-responders, according to the FCGR3A genotype, are 
shown in Table 3. Overall, there was a significant difference between genotypes (P = 0.01). The best response 
was observed in V/V homozygotes and the worst response was found in F/F homozygotes. The most striking 
difference was observed when looking at the response rate (complete or partial) among V/V homozygotes when 
compared with other genotypes (Figure 1). The median δCRP (relative value) was -80.1% (range. -31.0% to        
-94.8%) in V/V homozygotes vs. - 63.2% (range. + 1100% to -98.1%) in V/F and F/F patients together (P = 
0.0078) (Figure 2). The median δCRP (absolute value, normalized) was -8.0 (range, -1.0 to -119.0) in V/V 
patients vs. -6.6 (range, +107.0 to -58) in the F carrier group (P = 0.05). 
The frequencies of clinical complete, partial and non-responders, according to the FCGR3A genotype, in the sub-
group of 145 patients (including 1.13 luminal and 32 fistulizing Crohn's disease) with elevated CRP before 
treatment, are shown in Figure 3. Globally, there was no significant difference but, when comparing only the 
frequencies of non-responders with complete and partial responders grouped together, there was a trend towards 
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Table 2. Clinical response to infliximab according to PCGR3A genotype (%) 
Genotype Complete response Partial response Non-responders 
All patients (n = 200) 
V/V (n = 35) 21 (60.0) 8 (22.9) 6 (17.1) 
V/F (n = 100) 51 (51.0) 22 (22.0) 27 (27.0) 
F/F (n= 65) 34 (52.3) 13 (20.0) 18 (27.7) 
Non-fistulizing disease (n = 142) 
V/V (n = 12) 13 (59,1) 6 (27.3) 3 (13.6) 
V/P (n= 74) 44 (59.5) 14 (18.9) 16 (21.6) 
F/F (n = 46) 22 (47.8) 10 (21.7) 14 (30.5) 
Fistulizing disease (n = 58) 
V/V (n = 13) 8 (61.5) 2 (15.4) 3 (23.1) 
V/F (n = 26) 7 (26.9) 8 (30.8) 11 (42.3) 
F/F (n = 19) 12 (63.2) 3 (15.8) 4 (21.0) 
 
Table 3. Biological response to infliximab according to PCGR3A genotype (%) 
Genotype Complete response Partial response Non-responders 
All patients* (n = 145) 
V/V (n = 29) 13 (44.8) 16 (55.2) 0 (0) 
V/F (n= 71) 27 (38.0) 24 (33.8) 20 (28.2) 
F/F (n = 45) 12 (26.7) 18 (40.0) 15(33.3) 
Complete response, normalization of C-reactive protein 4 weeks after treatment. 
Partial response, decrease in C-reactive protein of at least 25% 
4 weeks after treatment. 
P = 0.01 (3 × 3 contingency table). 
* Including 113 luminal and 32 fistulizing disease. 
 
Multivariate analyses 
The logistic regression with clinical response as the dependent variable, on the whole group of patients for whom 
all clinical, demographic and biological data were available before treatment (n = 189), identified the use of 
immunosuppressive drugs and an elevated CRP level (greater than twice the upper limit of the normal range) as 
factors predictive of response (P = 0.003). The logistic regression with biological response as the dependent 
variable, on the sub-group of 145 patients with an elevated CRP before treatment, could not be performed 
because the FCGR3A genotype gave a complete separation of the patients (100% of responders amongst the V/V 
homozygotes). The logistic regression with clinical response as the dependent variable, on the sub-group of 145 
patients with elevated CRP before treatment, selected the use of immunosuppressive drugs and the FCGR3A-
158V/V genotype as factors predictive of response (P = 0.003). 
Figure 1. Biological response to infliximab in patients with elevated C-reactive protein (CRP) (greater than 
twice the upper limit of the normal range) before treatment according to FCGR3A-158 genotype. Complete and 
partial biological responses were defined as a normalization of CRP or a decrease of at least 25%. respectively, 
4 weeks after treatment. CI. confidence interval: RR. relative risk. 
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DISCUSSION 
Our results show a significant association between a biological response to infliximab, assessed by the variation 
in CRP level, and a single nucleotide polymorphism in the FCGR3A gene, which codes for a receptor for the Fc 
portion of IgG (FcγR) on natural killer cells and macrophages. There was also a trend towards an association 
between this polymorphism and a clinical response to infliximab.  
Several arguments may explain why the FCGR3A effect was more prominent when a biological marker was 
considered (the CRP serum concentration), related to mucosal immuno-inflammatory processes, rather than the 
clinical response (adopting a CDAI decrease of 70 or 100 points). First, a clinical evaluation of the response to 
treatment is sometimes difficult in Crohn's disease and the correlation between clinical and biological parameters 
is poor.30, 31 Second, the symptoms and clinical activity in Crohn's disease may result from a wide range of 
factors, and not only inflammation which is targeted by infliximab. Finally, certain non-responses to infliximab 
may be related to an absence of significant inflammation before treatment,9 such as in clinical forms of Crohn's 
disease characterized by a predominance of irritable bowel syndrome, or post-surgical symptoms for which 
infliximab has no impact and the FCGR3A gene polymorphism no influence. Indeed, when the sub-group of 
patients with elevated CRP before treatment was selected, a trend towards an association between the FCGR3A 
gene polymorphism and a clinical response to infliximab was observed.  
Similar to rituximab used in the treatment of follicular non-Hodgkin's lymphomas.24, 25 FCGR3A-158V/V 
homozygous patients developed a better response to infliximab, whereas sub-optimal responses were observed in 
F/F homozygotes. According to the association suggested by the clinical response to rituximab.24, 25 
V homozygosity confers a functional advantage, whereas the carriage of a single V allele in heterozygotes does 
not seem to be sufficient for a better response than in F homozygotes. This is the reason why the majority of the 
analyses were performed by grouping V/F and F/F patients together. The most striking difference concerned the 
proportion of biological non-responses: none in V/V patients vs. 30.2% in F carriers. This difference was also 
noted for the clinical response (although not statistically significant): in patients with elevated CRP before 
treatment, only 13.8% of V/V patients did not clinically respond vs. 27.6% of F carriers; in the whole group of 
patients, 17.1% of the V/V patients showed no response vs. 27.3% of F carriers. An analysis of a larger number 
of patients will be required to reach a more striking statistical significance concerning the association between 
the FCGR3A polymorphism and the clinical response to infliximab. According to our data, however, for a given 
patient, the predictive value of the FCGR3A genotype on the clinical response to infliximab in Crohn's disease is 
low. 
Figure 2. Variation in the relative value of C-reactive protein (CRP) 4 weeks after infliximab treatment 
(compared with baseline) according to FCGR.3A-158 genotype. (a) Relative CRP variation in F carriers (V/F 
and F/F genotypes): the median variation was - 63.2% (range, + 1100% to - 98.1%). (b) Relative CRP variation 
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Figure 3. Clinical response to infliximab according to FCGR3A-158 genotype in a sub-group of patients with 
elevated C-reactive protein (CRP) (greater than twice the upper limit of the normal range) before treatment. For 
luminal Crohn's disease (n = 113), complete and partial responders were defined by a Crohn's disease activity 
index (CDAI) below 150 or a decrease of at least 70 points 4 weeks after treatment, respectively. For fistulizing 
Crohn's disease (n= 32),  patients were considered as complete or partial responders at week 10 according to 
complete fistula closure or a decrease of at least 50% in fistula drainage at two consecutive visits, respectively. 
 
 
The response to infliximab treatment is probably a complex phenomenon influenced by several parameters. In 
this model, the individual impact of each particular factor may not be very strong. So far. various clinical and 
demographic parameters, including the use of immunosuppressive drugs6, 7 a young age.6 colonic location,6 non-
smoking7 and elevated CRP.9 have been associated with a positive clinical response to infliximab, but no 
relevant pharmacogenetic association has been established. We studied all of these clinical and demographic 
parameters in a multivariate analysis with clinical response as the dependent variable. This analysis identified the 
use of immunosuppressive drugs and the presence of an elevated CRP level as factors predictive of a response to 
infliximab. In the sub-group of patients with an elevated CRP before treatment, the multivariate analysis 
identified the use of immunosuppressive drugs and the FCGR3A polymorphism as predictive factors. These 
results strengthen the case for a significant influence of the FCGR3A genotype on the response to infliximab, 
independent of other factors previously identified.7 
The FCGR3A gene studied encodes FcγRIIIa. a receptor for the Fc portion of IgG expressed on macrophages and 
natural killer cells and involved in antibody-dependent cell-mediated cytotoxicity. This mechanism has been 
identified in vitro using infliximab and cells bearing transmembrane TNF-α.l8 The relative importance of 
antibody-dependent cell-mediated cytotoxicity in the therapeutic efficacy of infliximab in vivo, in addition to 
other mechanisms described in vitro, such as complement activation,18 apoptosis induction17 or TNF-α 
neutralization,32 is not known. However, the superiority of infliximab over etanercept in the treatment of Crohn's 
disease33 may be linked to a different ability to bind transmembrane TNF-α and. consequently, to induce the 
killing of activated TNF-α-positive mononuclear cells.34 Indeed, although the capacity to bind soluble TNF-α 
was similar with the two drugs, only infliximab was able to induce apoptosis of activated lymphocytes in vitro.34 
In this in vitro model, neither complement-mediated nor cell-mediated lymphocyte lysis seemed to be involved. 
In another model, however, infliximab and etanercept also showed a different ability to mediate complement-
dependent killing of TNF-α-expressing cells.35 In vivo, as demonstrated in some in vitro experiments.18, 36 cell-
mediated lysis, as a consequence of infliximab binding to transmembrane TNF-α, may further contribute to the 
efficacy of infliximab. The functionally significant FCGR3A-15S polymorphism may thus have an impact on 
infliximab efficacy by influencing its ability to kill mucosal mononuclear cells through antibody-dependent cell-
mediated cytotoxicity, and thus may influence the rate of sustained response measured 4 weeks after treatment. 
This suggests that antibody-dependent cell-mediated cytotoxicity is one of the mechanisms involved in the 
action of infliximab, and that V/V patients are more likely than F carriers to have at least a biological response 
through this mechanism. However, further genetic studies (excluding linkage disequilibrium) and in vitro 
experiments will be required to demonstrate these hypotheses. 
In conclusion, our results show, for the first time, a relevant pharmacogenetic association for infliximab in 
Crohn's disease. They suggest a role for FcγR and probably antibody-dependent cell-mediated cytotoxicity 
amongst the mechanisms of action of infliximab in Crohn's disease. Finally, they also emphasize the need for a 
biological, and not only clinical, assessment of response in Crohn's disease when studying new drugs, especially 
in pharmacogenetic investigations. 
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